EarningsQ2 2026 Earnings Report
DE:8EQ Q2 2026 EPS Results
Actual EPS-€0.08
Consensus EPS-€0.08
Beat/MissBeat by +<€0.01
One Year Ago EPS-€0.04
DE:8EQ Q2 2026 Revenue Results
Actual Revenue€43.10M
Expected Revenue€42.36M
Beat/MissBeat by +€743.10K
YoY Revenue Growth+5.57%
Earnings Announcement Details
QuarterQ2 2026
Date08/05/2026
TimeAfter Close
Conference CallWednesday, August 5, 2026
DE:8EQ Upcoming Earnings
Cytek Biosciences's next earnings date is estimated for November 11, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
DE:8EQ Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presents a mixed but cautiously constructive picture: revenue growth (6% YoY) driven by strong performance in the U.S. and China, expansion of installed base, growing recurring revenue (35% of LTM), and strategic product launches (Borealis and Aurora Evo) underpin future upside. Offsetting these positives are widening GAAP losses, a Q2 adjusted EBITDA decline, regional weaknesses in EMEA and parts of APAC, rising operating expenses (including litigation-related G&A increases), and some one-time items (tariff refund, investment write-off) that cloud margin comparability. Management raised the low end of guidance and expects H2 improvement, but several challenges (regional budgetary pressures, delayed clinical penetration in the U.S., and reorganization timeline) temper near-term outlook.Company Guidance
Quarterly Revenue Growth
Q2 2026 revenue of $48.1 million, up 6% year-over-year (compared to $45.6M in Q2 2025).
Strong U.S. Performance
U.S. revenue of $28.2 million, up 18% year-over-year and a record quarter in the U.S.; growth driven by instrument revenue in academic & government and services.
China and APAC Momentum (Selective)
China delivered strong double-digit growth in Q2; total APAC revenue was $7.9 million, flat YoY, with China offsetting softness in other APAC markets.
Product and Instrument Strength
Product revenue was $32.6 million, up 4% YoY; sales of high-end instruments grew mid-teens in Q2 and high-end FSP instrument portfolio units grew 11% YoY.
Installed Base Expansion
Added 142 units in the quarter, bringing total installed base to 3,933 units, supporting recurring revenue growth and service demand.
Recurring Revenue Growth
Combined reagent and service revenue of $18.5 million, up 8% YoY; service revenue $15.6 million, up 10% YoY. Recurring revenue now represents 35% of trailing 12 months revenue (up from 32%).
New Product Launches — Borealis and Aurora Evo
Introduced Borealis (industry-first 60-color, 7-laser full-spectrum cytometer) and Aurora Evo with expanded automation/remote operation and API — early customer feedback strong and positioned to expand market opportunities in high-parameter and automated workflows.
Cytek Cloud User Growth
Cytek Cloud surpassed 28,000 users as of June 30, 2026, up 15% since the start of the year, strengthening ecosystem engagement and driving reagent/service adoption.
Gross Margin Resilience (Including One-Time Item)
GAAP gross profit $28.3 million and GAAP gross margin 59% in Q2, which includes a one-time $2.8 million tariff refund. Excluding the refund, gross margin would have been 53% vs 52% in Q2 2025; adjusted gross margin was 61% (56% excluding refund) vs 56% prior year.
Balance Sheet and Liquidity
Cash, cash equivalents and marketable securities totaled $262 million as of June 30, 2026, essentially flat quarter-over-quarter, supporting financial flexibility for investments and growth.
Raised Low End of Full-Year Revenue Guidance
Revised 2026 revenue guidance to $207 million–$212 million, increasing the midpoint by $1 million; company expects second-half seasonality with Q4 materially higher than Q3.
DE:8EQ Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed